1. Home
  2. SLXN vs AMST Comparison

SLXN vs AMST Comparison

Compare SLXN & AMST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • AMST
  • Stock Information
  • Founded
  • SLXN 2008
  • AMST 2017
  • Country
  • SLXN Israel
  • AMST United States
  • Employees
  • SLXN N/A
  • AMST N/A
  • Industry
  • SLXN
  • AMST Computer Software: Prepackaged Software
  • Sector
  • SLXN
  • AMST Technology
  • Exchange
  • SLXN NYSE
  • AMST Nasdaq
  • Market Cap
  • SLXN 7.3M
  • AMST 9.5M
  • IPO Year
  • SLXN N/A
  • AMST 2020
  • Fundamental
  • Price
  • SLXN $0.80
  • AMST $2.77
  • Analyst Decision
  • SLXN Strong Buy
  • AMST
  • Analyst Count
  • SLXN 1
  • AMST 0
  • Target Price
  • SLXN $5.00
  • AMST N/A
  • AVG Volume (30 Days)
  • SLXN 141.1K
  • AMST 37.4K
  • Earning Date
  • SLXN 08-21-2025
  • AMST 05-15-2025
  • Dividend Yield
  • SLXN N/A
  • AMST N/A
  • EPS Growth
  • SLXN N/A
  • AMST N/A
  • EPS
  • SLXN N/A
  • AMST N/A
  • Revenue
  • SLXN N/A
  • AMST $82,544.00
  • Revenue This Year
  • SLXN N/A
  • AMST N/A
  • Revenue Next Year
  • SLXN N/A
  • AMST N/A
  • P/E Ratio
  • SLXN N/A
  • AMST N/A
  • Revenue Growth
  • SLXN N/A
  • AMST N/A
  • 52 Week Low
  • SLXN $0.58
  • AMST $2.00
  • 52 Week High
  • SLXN $41.85
  • AMST $6.27
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • AMST 51.42
  • Support Level
  • SLXN N/A
  • AMST $2.51
  • Resistance Level
  • SLXN N/A
  • AMST $2.82
  • Average True Range (ATR)
  • SLXN 0.00
  • AMST 0.15
  • MACD
  • SLXN 0.00
  • AMST -0.01
  • Stochastic Oscillator
  • SLXN 0.00
  • AMST 46.64

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

About AMST Amesite Inc.

Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.

Share on Social Networks: